Proteon Therapeutics
American pharmaceutical company
TARA Nasdaq
SEC CIK 1359931
Follow Proteon Therapeutics
Weekly email: filings, results
Net income
−$21.7M
−63.6% vs same quarter last year
EPS, diluted
−$0.35
−12.9% vs same quarter last year
Operating cash flow
−$18.4M
−48.1% vs same quarter last year
Operating income
−$23.2M
−56.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$57.4M |
| FY24 | −$44.6M |
| FY23 | −$40.4M |
| FY22 | −$66M |
| FY21 | −$47.3M |
| FY20 | −$34M |
| FY19 | −$7.8M |
| FY18 | −$20.7M |
| FY17 | −$30M |
| FY16 | −$28.5M |
| FY15 | −$21.4M |
| FY14 | −$3.3M |
| FY13 | −$7.9M |
| FY12 | −$8M |
| FY11 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$56.5M |
| FY24 | −$35.9M |
| FY23 | −$37.6M |
| FY22 | −$26.6M |
| FY21 | −$35.1M |
| FY20 | −$24.3M |
| FY19 | −$5.5M |
| FY18 | −$23.4M |
| FY17 | −$22.4M |
| FY16 | −$24M |
| FY15 | −$17.8M |
| FY14 | −$10M |
| FY13 | −$6.7M |
| FY12 | −$8.3M |
| FY11 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | $91K |
| FY22 | $90K |
| FY21 | $228K |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
| FY11 | - |